CV effects of ASA

CV effects of ASA

ASA is a well-established therapy for secondary prevention of myocardial infarction (MI) in patients with known CAD. This is accomplished through inhibition of COX-1 and subsequent decline in TXA 2 , a potent platelet activator. It is an ideal agent for several reasons: (1) COX-1, but not COX-2; is expressed in mature platelets; (2) ASA is a COX-1-specific inhibitor; (3) ASA works through irreversible binding to the COX-1 enzyme, providing stable suppression of enzyme activity; and (4) evidence demonstrates “ASA-triggered” production of antiinflammatory mediators such as lipoxins and resolvins. Other traditional NSAIDs that inhibit COX-1 can reversibly inhibit platelets, but there is no definitive evidence of cardioprotection with these agents.


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information